QLGN - צמיחת רווח נקי למניה משנה לשנה ב-12 החודשים האחרונים Qualigen

Quarterly earnings per share growth reflects volatile market expectations, where 0.30 indicates the current level for Qualigen Therapeutics (QLGN). This price action is driven by management restructuring focused on oncology and cost optimization. Growth potential is based on the mass adoption of diagnostic systems. The stability of the R&D core and the retention of leading virologists ensure the protection of Qualigen Therapeutics (QLGN) intellectual capital during this transformation period.

For Qualigen Therapeutics (QLGN), which is transitioning toward the development of oncology drugs, profit dynamics are critical, as R&D costs often outpace revenue. By analyzing the growth rates of quarterly net income per share, an investor tracks the velocity of EPS changes, which allows for the timely detection of business stagnation and the avoidance of purchasing overvalued assets amid the company's liquidity shortage.